StockNews.com Begins Coverage on LifeVantage (NASDAQ:LFVN)

Investment analysts at StockNews.com assumed coverage on shares of LifeVantage (NASDAQ:LFVN – Get Rating) in a research report issued on Wednesday. The brokerage set a “strong-buy” rating on the stock.

LifeVantage Price Performance

Shares of LFVN opened at $3.83 on Wednesday. The stock’s 50-day moving average is $3.80 and its two-hundred day moving average is $3.89. The stock has a market cap of $48.14 million, a PE ratio of 95.75 and a beta of 1.10. LifeVantage has a 12 month low of $3.46 and a 12 month high of $6.68.

LifeVantage (NASDAQ:LFVN – Get Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported $0.06 EPS for the quarter. The company had revenue of $51.77 million for the quarter. LifeVantage had a return on equity of 9.48% and a net margin of 0.20%. On average, research analysts anticipate that LifeVantage will post 0.33 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its stake in shares of LifeVantage by 117.5% in the third quarter. Tower Research Capital LLC TRC now owns 11,362 shares of the company’s stock worth $42,000 after acquiring an additional 6,138 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of LifeVantage by 0.3% in the second quarter. Renaissance Technologies LLC now owns 974,318 shares of the company’s stock worth $4,238,000 after acquiring an additional 3,300 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its stake in shares of LifeVantage by 61.8% in the second quarter. O Shaughnessy Asset Management LLC now owns 24,368 shares of the company’s stock worth $106,000 after acquiring an additional 9,312 shares in the last quarter. Private Advisor Group LLC acquired a new position in shares of LifeVantage in the second quarter worth about $49,000. Finally, EP Wealth Advisors LLC acquired a new position in shares of LifeVantage in the first quarter worth about $234,000. Institutional investors and hedge funds own 29.69% of the company’s stock.

LifeVantage Company Profile

(Get Rating)

LifeVantage Corp. engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and personal care products. The firm operates through the following geographical segments: Americas Region, and Asia/Pacific and Europe Region. Its products include Protandim, LifeVantage Omega+ and ProBio, TrueScience and Petandim for dogs.